1,25-dihydroxy Vitamin D3 and Interleukin-6 Blockade Synergistically Regulate Rheumatoid Arthritis by Suppressing Interleukin-17 Production and Osteoclastogenesis.

Haneul Kim Seungye Baek Seung-Min Hong Jaeseon Lee Seung-Min Jung Jennifer Jooha Lee Mi-La Cho Seung Ki Kwok Sung Hwan Park

Published in: Journal of Korean medical science (2020)

RA patients treated with IL-6 antibody show a better response when they have sufficient serum vit D. Tocilizumab and 1,25(OH)₂D synergistically suppress IL-17 production and osteoclast differentiation in RA patients.

Keyphrases

rheumatoid arthritis
disease activity
end stage renal disease
chronic kidney disease
ejection fraction
ankylosing spondylitis
peritoneal dialysis
prognostic factors
patient reported outcomes
bone loss
juvenile idiopathic arthritis